Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay

Cancer Research

Volumn 69, Issue 14, 2009, Pages 5867-5875

  Zhang, Yimao ^a   Byun, Youngjoo ^a   Ren, Yunzhao R ^a   Liu, Jun O ^a   Laterra, John ^a   Pomper, Martin G ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANT PROTEIN INHIBITOR; CALCIMYCIN; CLEBOPRIDE MALEATE; CURCUMIN; DIHYDROERGOTAMINE MESILATE; DIPYRIDAMOLE; DOXAZOSIN MESYLATE; FLAVOXATE; FUMITREMORGIN C; GEFITINIB; GLAFENINE; GRAMICIDIN A; HARMALINE; HARMINE; HESPERETIN; ISORHAMNETIN; MEPACRINE; NELFINAVIR; NIGULDIPINE; PRAZOSIN; PROTEIN INHIBITOR; RESERPINE; RIBOFLAVIN; ROTENONE; SILVER NITRATE; TRACAZOLATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VERTEPORFIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOLUMINESCENCE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG IDENTIFICATION; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSPLANTATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLAFENINE; HUMANS; INJECTIONS, INTRAVENOUS; LUCIFERASES; LUMINESCENT MEASUREMENTS; LUNG NEOPLASMS; MICE; MICE, NUDE; MITOXANTRONE; NEOPLASM PROTEINS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 67651000082     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4866     Document Type: Article

References (45)

1. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998;95:65-70.
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev 2006;5:219-34.
3. Benderra Z, Faussat AM, Sayada L, et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004;10:7896-902.
4. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Met Rev 2007;26:39-57.
5. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotech 2007;18:460-6.
6. Zhang Y, Bressler JP, Neal J, et al. ABCG2/BCRP expression modulates D-luciferin based bioluminescence imaging. Cancer Res 2007;67:9389-97.
7. Rettig GR, McAnuff M, Liu D, Kim JS, Rice KG. Quantitative bioluminescence imaging of transgene expression in vivo. Analytic Biochem 2006;355:90-4.
8. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000;60:47-50.
9. Brovko LY, Griffiths MW. Illuminating cellular physiology: recent developments. Sci Prog 2007;90:129-60.
10. Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ, Jr. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 2006;2:415-6.
11. Chong CR, Qian DZ, Pan F, et al. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem 2006;49: 2677-80.
12. Zhang Y, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia 2009;11:96-101.
13. Robey RW, Honjo Y, van de Laar A, et al. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 2001; 1512:171-82.
14. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
15. Robey RW, Honjo Y, Morisaki K, et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Brit J Cancer 2003;89:1971-8.
16. Nakamura Y, Oka M, Soda H, et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005;65:1541-6.
17. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-34.
18. Zhang Y, Gupta A, Wang H, et al. BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharma Res 2005;22:2023-34.
19. Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cel Biochem 2007; 296:85-95.
20. Ahmed-Belkacem A, Pozza A, Macalou S, Perez-Victoria JM, Boumendjel A, Di Pietro A. Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2). Anti-cancer Drugs 2006;17:239-43.
21. Ö zvegy C, Litman T, Szakacs G, et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophysic Res Commun 2001;285:111-7.
22. Ö zvegy C, Varadi A, Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J Biologic Chem 2002;277:47980-90.
23. Henrich CJ, Bokesch HR, Dean M, et al. A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen 2006;11:176-83.
24. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Brit J Cancer 2000;83:366-74.
25. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ann Rev Pharmacol Toxicol 1999;39:361-98.
26. Shen DW, Cardarelli C, Hwang J, et al. Multiple drugresistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biologic Chem 1986;261:7762-70.
27. Auld DS, Southall NT, Jadhav A, et al. Characterization of chemical libraries for luciferase inhibitory activity. J Med Chem 2008;51:2372-86.
28. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58.
29. Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T. The role of half-transporters in multidrug resistance. J Bioenergetics Biomembranes 2001;33:503-11.
30. Perez-Prieto J, Galian RE, Morant-Minana MC. Aromatic ketones as photocatalysts: combined action as triplet photosensitiser and ground state electron acceptor. Chemphyschem 2006;7:2077-80.
31. Matsumoto T, Urano Y, Shoda T, Kojima H, Nagano T. A thiol-reactive fluorescence probe based on donorexcited photoinduced electron transfer: key role of ortho substitution. Organic Lett 2007;9:3375-7.
32. Ulrich G, Ziessel R, Harriman A. The chemistry of fluorescent bodipy dyes: versatility unsurpassed. Angew Chem Int Ed Engl 2008;47:1184-201.
33. Koenig MBP, Zieg H, Ritter T, Bouas-Laurent H, Bonneau R, Desvergne J-P. Photoinduced electron transfer in a phenothiazine-riboflavin dyad assembled by zincimide coordination in water. J Am Chem Soc 1999;121:7.
34. Le SB, Holmuhamedov EL, Narayanan VL, Sausville EA, Kaufmann SH. Adaphostin and other anticancer drugs quench the fluorescence of mitochondrial potential probes. Cell Death Diff 2006;13:151-9.
35. Rajagopal A, Simon SM. Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell 2003;14:3389-99.
36. Mogi M, Yang J, Lambert JF, et al. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biologic Chem 2003;278:39068-75.
37. Weiss J, Rose J, Storch CH, et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrobial Chemother 2007;59:238-45.
38. Liu H, Cheng D,Weichel AK, et al. Cooperative effect of gefitinib and fumitremorgin C on cell growth and chemosensitivity in estrogen receptor a negative fulvestrant-resistant MCF-7 cells. Int J Oncol 2006;29:1237-46.
39. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 2004;3:1119-25.
40. Zamek-Gliszczynski MJ, Nezasa K, Tian X, et al. The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 2006;70:2127-33.
41. Litman T, Brangi M, Hudson E, et al. The multidrugresistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000;113:2011-21.
42. Chearwae W, Shukla S, Limtrakul P, Ambudkar SV. Modulation of the function of the multidrug resistancelinked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol Cancer Ther 2006;5:1995-2006.
43. Zhou XF, Yang X, Wang Q, Coburn RA, Morris ME. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Drug Metab Dispos 2005;33: 1220-8.
44. van Herwaarden AE, Wagenaar E, Merino G, et al. Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol 2007;27:1247-53.
45. Cooray HC, Janvilisri T, van Veen HW, Hladky SB, Barrand MA. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophysic Res Commun 2004;317:269-75.